Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.80 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5012922 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL2034531 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL8326268 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL5576238 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL108703 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL5081413 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL4827556 | 1.00 | CA1 (0.80) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL9650988 | 0.95 | CA1 (0.73) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL7567062 | 0.95 | CA1 (0.82) | CA1CA4LMNATSHRFFAR3 | |
| Acetic Acid SCHEMBL15572284 | 0.95 | CA1 (0.73) | CA1CA4LMNATSHRFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| WO-2024124092-A2 | PRODRUGS OF TEMOZOLOMIDE TO FACILITATE DELIVERY INTO BRAIN TUMORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024124232-A1 | NUCLEIC ACID BASED CANCER VACCINE AND METHODS THEREOF | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240173374-A1 | LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| US-11986459-B2 | Methods for the treatment of Mycobacterium infections | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| US-20240140952-A1 | INHIBITORS AND DEGRADERS OF JANUS KINASE 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-02 | — | — | US | disclosed |
| US-20240131047-A1 | SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-25 | — | — | US | disclosed |
| WO-2024086708-A2 | COMPOSITIONS AND METHODS FOR PREVENTING CARDIOMYOPATHY | OHIO STATE INNOVATION FOUNDATION (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11951152-B1 | Microparticle compositions for controlled delivery of telmisartan and actinomycin D | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-04-09 | — | — | US | disclosed |
| US-20130041311-A1 | METHODS, DEVICES, AND SYSTEMS FOR ON-DEMAND ULTRASOUND-TRIGGERED DRUG DELIVERY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120156300-A1 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY | THE TRUSTEES OF COLUMBIA UNIVERSITY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20090191244-A1 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
| US-20060122089-A1 | Detergent or cleaning agent | HENKEL AG & CO. KGAA (DE) | 2006-06-08 | — | — | US | disclosed |
| US-20060116309-A1 | Detergent or cleaning agent | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-0958306-B1 | CARBOXYALKYL CELLULOSE ESTERS | EASTMAN CHEM CO (US) | 2002-10-30 | — | — | EP | disclosed |
| US-5644019-A | High activity catalytic system for the synthesis of poly(ethylene terephthalate) | ENICHEM S.P.A. (IT) | 1997-07-01 | — | — | US | disclosed |
| EP-0745630-A2 | High activity catalytic system for the synthesis of poly(ethylene terephthalate) | ENICHEM S.p.A. (IT) | 1996-12-04 | — | — | EP | disclosed |
| US-5458949-A | Biaxial orientation; polyester blend comprising polybutylene terephthalate and at least one other polyester | DIAFOIL HOECHST COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| US-5446156-A | Mixing water soluble carboxylic or hydrohalic acid with aqueous solution having dissolved ammonium or alkali metal salt of tetrahydrofoic acid derivative, adding alkaline metal salts, precipitation, acidification again, separation of solid | SAPEC S.A. FINE CHEMICALS (CH) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173374-A1 | LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS | LIPA, CHMP4B, VMA21 | CA1 1208/4885CA4 476/4885LMNA 731/4885 |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | CA1 3514/4885CA4 2914/4885LMNA 3942/4885 |
| US-11951152-B1 | Microparticle compositions for controlled delivery of telmisartan and actinomycin D | CRH, ANXA6, CTSD | CA1 4711/4885CA4 4648/4885LMNA 1149/4885 |
| US-20240131047-A1 | SMALL MOLECULE INHIBITORS OF CD38 AS IMMUNOSUPPRESSANTS | CD38, CD2, CD58 | CA1 2049/4885CA4 2905/4885LMNA 4506/4885 |
| US-20240140952-A1 | INHIBITORS AND DEGRADERS OF JANUS KINASE 2 | JAK2, JAK1, JAK3 | CA1 4694/4885CA4 4376/4885LMNA 4524/4885 |
| US-11986459-B2 | Methods for the treatment of Mycobacterium infections | CLTB, IFNG, NDUFB7 | CA1 4809/4885CA4 2487/4885LMNA 2334/4885 |
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | CTRL, SERPINB1, PRSS1 | CA1 339/4885CA4 901/4885LMNA 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.